Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis – Relationship between disease activity of rheumatoid arthritis and anemia

Suzuki, Satoshi; Nakano, Souichiro; Ando, Seiichiro; Matsudaira, Ran; Kanai, Yoshikatsu; Yamanaka, Kenjiro; Takasaki, Yoshinari

doi:10.1016/j.rbre.2016.09.004

Cited by 6 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in the same study of patients with RA, iron metabolism was related to serum hepcidin levels cross-sectionally, but inflammation was related longitudinally 19 . Anti-IL-6 therapy decreases serum hepcidin and improves the Hb level [20][21][22] , and the effect is more marked with anti-IL-6 than anti-TNF therapy 20 . In our cross-sectional study, CRP and Hb were related to the serum hepcidin level, but stronger relationships were www.nature.com/scientificreports www.nature.com/scientificreports/ observed for iron metabolism (i.e., ferritin, iron, and UIBC).…”

Section: Discussionmentioning

confidence: 99%

Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis

Sato

Takai

Kazama

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Hepcidin, a major regulator of iron metabolism and homeostasis, is regulated by inflammation. Recent studies have suggested that hepcidin and iron metabolism are involved in osteoporosis, and the aim of this study was to determine whether serum hepcidin levels are correlated with the degree of osteoporosis in patients with rheumatoid arthritis (RA). A total of 262 patients with RA (67.5 ± 11.4 years; 77.5% female) were enrolled. Serum iron, ferritin, and hepcidin levels were positively correlated each other. Multiple regression analyses revealed that the serum iron level was positively correlated with femoral T and Z scores, whereas the serum hepcidin level was not. Serum hepcidin level was correlated with the serum 25-hydroxy vitamin D level, which was in turn positively related to the femoral Z score. Serum hepcidin and serum iron were indirectly and directly related to osteoporosis in patients with RA.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis

Sato

Takai

Kazama

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Importantly, one case of a switch from an effective ADA therapy (DAS28 = 2.9) due to the onset of moderate anemia was recorded. On the other hand, based on the fact that IL-6 is essential in anemia related to chronic diseases, it is possible that anti-IL6R therapy could improve anemia markers more effectively than other biologics (Suzuki et al, 2017[ 37 ]). Similar to Paul et al (2018[ 29 ]), our results show that TCZ but not anti-TNFα biologicals significantly increased the RBC and HGB levels.…”

Section: Discussionmentioning

confidence: 99%

Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications

Pereckova,

Martiniakova,

Payer

et al. 2022

EXCLI Journal; 21:Doc580; ISSN 1611-2156

View full text Add to dashboard Cite

Administration of biological therapy (BT) in rheumatoid arthritis (RA) patients is often associated with hematological complications, which result in switching among therapies. Thus, there is an instant need for suitable screening parameters that will help to individualize the therapy and minimize the onset of adverse effects. We analyzed the hematological profile of 99 RA patients receiving TNFα (Adalimumab - ADA, Golimumab - GOL, Etanercept - ETA) or IL-6 receptor (Tocilizumab - TCZ) inhibitors in order to find possible indicators to improve personalization of RA therapy. BTs significantly affect the levels of observed hematological parameters. In contrast to TNF-α inhibitors, TCZ normalized almost all monitored hematological parameters to values of healthy donors. Only GOL from the TNF-α inhibitors studied, was able to normalize neutrophil counts, as well as platelet indicators. Importantly, effects on the blood parameters (e.g. lymphocytes or platelet count) differ even within the same therapeutic group (anti-TNFα). Variable effects of individual biological agents in RA treatment point to importance to evaluate the patient's hematological profile to improve the selection of suitable BT. It will help to personalize the administration of BT and prevent unnecessary switching from an effective therapy just because of provocation of avoidable hematological complications.

show abstract

“…Suzuki et al . reported a decrease in hepcidin after 12 weeks of tocilizumab treatment in 10 adult patients with rheumatoid arthritis . Furthermore, the effects of tocilizumab and infliximab were compared in 93 adult patients with rheumatoid arthritis.…”

Section: Discussionmentioning

confidence: 99%

“…Suzuki et al reported a decrease in hepcidin after 12 weeks of tocilizumab treatment in 10 adult patients with rheumatoid arthritis. 13 Furthermore, the effects of tocilizumab and infliximab were compared in 93 adult patients with rheumatoid arthritis. The authors found a decrease in hepcidin, IL-6 and haemoglobin levels in both groups, but the decrease in hepcidin level was more pronounced in the tocilizumab group.…”

Section: Discussionmentioning

confidence: 99%

Changes in serum hepcidin levels in children with inflammatory bowel disease during anti‐inflammatory treatment

Karásková

Volejnikova

Holub

et al. 2019

J Paediatrics Child Health

View full text Add to dashboard Cite

Aim The aim of this study was to compare changes in serum hepcidin levels in paediatric patients with inflammatory bowel disease during therapy and correlate them with markers of iron metabolism, inflammation and type of treatment. Methods Children with newly diagnosed Crohn's disease (CD) and ulcerative colitis (UC) were included in this longitudinal study. Blood and stool samples were collected to assess levels of serum hepcidin and markers of iron metabolism parameters and inflammation. The parameters were examined before treatment (baseline levels) and compared with levels in the follow‐up period during maintenance therapy (mean follow‐up of 39 months after diagnosis). Results Patients with CD (n = 30) had higher serum hepcidin levels (expressed as a median and interquartile range) at diagnosis than subjects with UC (n = 13). These levels significantly decreased during the follow‐up (from 36.5 (11.5–79.6) to 2.1 (0.9–6.7) ng/mL). In contrast, no significant serum hepcidin level changes were observed in the UC patients (5.4 (3.4–16.6) vs. 4.8 (0.9–8.1) ng/mL). While hepcidin level changes correlated with disease activity and inflammatory parameters (erythrocyte sedimentation rate, C‐reactive protein), in CD patients, they correlated only with serum iron levels in patients with UC. Biological therapy was accompanied by a significant decrease in C‐reactive protein and interleukin‐6 compared to conventional anti‐inflammatory therapy in CD patients. Conclusions Children with CD had higher serum hepcidin levels on diagnosis compared to subjects with UC. During an anti‐inflammatory therapy, serum hepcidin decreased in the CD group but remained consistently low in children with UC.

show abstract

Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis – Relationship between disease activity of rheumatoid arthritis and anemia

Cited by 6 publications

References 12 publications

Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis

Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis

Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications

Changes in serum hepcidin levels in children with inflammatory bowel disease during anti‐inflammatory treatment

Contact Info

Product

Resources

About